These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 23829613)
1. Rethinking cancer vaccines to avoid T-cell traps. Peoples GE Immunotherapy; 2013 Jul; 5(7):665-8. PubMed ID: 23829613 [No Abstract] [Full Text] [Related]
2. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Schaed SG; Klimek VM; Panageas KS; Musselli CM; Butterworth L; Hwu WJ; Livingston PO; Williams L; Lewis JJ; Houghton AN; Chapman PB Clin Cancer Res; 2002 May; 8(5):967-72. PubMed ID: 12006508 [TBL] [Abstract][Full Text] [Related]
3. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. Harris RC; Chianese-Bullock KA; Petroni GR; Schaefer JT; Brill LB; Molhoek KR; Deacon DH; Patterson JW; Slingluff CL J Immunother; 2012 Jan; 35(1):78-88. PubMed ID: 22130163 [TBL] [Abstract][Full Text] [Related]
4. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice. Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. Slingluff CL; Petroni GR; Smolkin ME; Chianese-Bullock KA; Smith K; Murphy C; Galeassi N; Neese PY; Grosh WW; Nail CJ; Ross M; von Mehren M; Haas N; Boisvert ME; Kirkwood JM J Immunother; 2010; 33(6):630-8. PubMed ID: 20551833 [TBL] [Abstract][Full Text] [Related]
9. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Yamamoto K; Ueno T; Kawaoka T; Hazama S; Fukui M; Suehiro Y; Hamanaka Y; Ikematsu Y; Imai K; Oka M; Hinoda Y Anticancer Res; 2005; 25(5):3575-9. PubMed ID: 16101182 [TBL] [Abstract][Full Text] [Related]
10. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development. Huijbers EJ; Femel J; Andersson K; Björkelund H; Hellman L; Olsson AK Vaccine; 2012 Jan; 30(2):225-30. PubMed ID: 22079080 [TBL] [Abstract][Full Text] [Related]
11. Getting melanoma cells to stimulate with frequency. Carson WE J Clin Oncol; 2005 Dec; 23(35):8929-31. PubMed ID: 16260688 [No Abstract] [Full Text] [Related]
12. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697 [TBL] [Abstract][Full Text] [Related]
13. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Eggermont AM Clin Cancer Res; 2009 Nov; 15(22):6745-7. PubMed ID: 19903779 [TBL] [Abstract][Full Text] [Related]
14. Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. Laurent J; Speiser DE; Appay V; Touvrey C; Vicari M; Papaioannou A; Canellini G; Rimoldi D; Rufer N; Romero P; Leyvraz S; Voelter V J Immunother; 2010 Sep; 33(7):723-34. PubMed ID: 20664354 [TBL] [Abstract][Full Text] [Related]
15. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339 [TBL] [Abstract][Full Text] [Related]
16. A proposal for a simple and inexpensive therapeutic cancer vaccine. Fahrer AM Immunol Cell Biol; 2012 Mar; 90(3):310-3. PubMed ID: 21606943 [TBL] [Abstract][Full Text] [Related]